Tranzactioneaza Outlook Therapeutics (US.OTLK) - 1.2 USD (%) Tranzactioneaza
Indici
Descriere companie
Outlook Therapeutics, Inc. (https://outlooktherapeutics.com/) is a late clinical-stage biopharmaceutical company. The Company is engaged in developing ophthalmic formulation of bevacizumab for use in retinal indications. bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. The Company is developing a product candidate namely ONS-5010 (LYTENAVA (bevacizumab-vikg)), which is an investigational ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The Company’s product candidate ONS-5010 for wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. It is also developing ONS-5010 (LYTENAVA (bevacizumab-vikg)) for the treatment of diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).